Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$161.01 - $317.85 $53.9 Million - $106 Million
334,751 Added 1473.25%
357,473 $113 Million
Q3 2023

Nov 14, 2023

SELL
$164.66 - $218.08 $4.51 Million - $5.97 Million
-27,378 Reduced 54.65%
22,722 $3.84 Million
Q2 2023

Aug 14, 2023

BUY
$176.32 - $240.22 $8.83 Million - $12 Million
50,100 New
50,100 $10.9 Million
Q3 2022

Nov 14, 2022

SELL
$123.79 - $277.42 $16.4 Million - $36.7 Million
-132,150 Reduced 90.06%
14,585 $3.28 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $5.71 Million - $8.71 Million
60,745 Added 70.64%
146,735 $18.6 Million
Q1 2022

May 16, 2022

BUY
$98.9 - $132.37 $6.85 Million - $9.16 Million
69,226 Added 412.94%
85,990 $10.9 Million
Q4 2021

Feb 14, 2022

BUY
$110.64 - $159.4 $674,461 - $971,702
6,096 Added 57.14%
16,764 $2.2 Million
Q1 2021

May 17, 2021

BUY
$95.46 - $133.08 $1.02 Million - $1.42 Million
10,668 New
10,668 $1.28 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.